Novadiscovery

Nova In SilicoHealthtechFrance

91% match

Nova In Silico provides a collaborative clinical trial simulation platform called jinkō, which uses disease models and virtual patient populations to predict clinical outcomes. The company serves pharmaceutical and biotech organizations by helping them optimize trial design, reduce risks to human subjects, and accelerate drug development from discovery to market access.

Simulations Plus, Inc. (SLP) is a worldwide developer of sophisticated software and services aimed at enhancing drug discovery and development processes. The company employs artificial intelligence and machine learning technologies to create tools for modeling, simulation, and predicting molecular characteristics. Its operations are divided into four main business units: Simulations Plus, Cognigen, DILIsym, and Lixoft. Among its diverse software offerings are GastroPlus, which models the absorption and drug interactions of compounds in both human and animal subjects, as well as DDDPlus and MembranePlus for various simulations. The company also provides a range of products built on mechanistic and mathematical models, such as its quantitative systems pharmacology software like DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym. Furthermore, Simulations Plus offers the ADMET Predictor, a chemistry-focused computer program that forecasts molecular properties from structural inputs, alongside MedChem Designer, MonolixSuite, and PKPlus for additional modeling and simulation needs. Beyond software, the company extends its expertise through various services, including contract research for population modeling and simulation, specialized training and consultation to advance pharmacometrics studies, and clinical-pharmacology consulting to aid in regulatory submissions. Simulations Plus serves a broad spectrum of clients globally, including pharmaceutical, biotechnology, agrochemical, cosmetic, and food companies, as well as academic institutions and regulatory bodies. The company was founded in 1996 and maintains its headquarters in Lancaster, California.

ArcaScienceHealthtechFrance

65% match

ArcaScience is a pharmaceutical artificial intelligence company headquartered in Paris, France, that develops an advanced benefit-risk decision engine and drug safety platforms.

VeriSIM LifeBiotechUnited States

76% match

VeriSIM Life provides an AI-driven drug discovery and development platform called BIOiSIM that uses mechanistic and quantitative methods to predict patient outcomes and de-risk clinical trials. The company serves pharmaceutical companies, biotechnology firms, and academic research institutions by generating actionable insights for drug repurposing, safety-toxicity profiles, and efficacy predictions.

InSilicoTrialsHealthcareItaly

74% match

InSilicoTrials is a healthcare technology company headquartered in Trieste, Italy, specializing in computational modeling and AI. The platform helps pharmaceutical and device developers run clinical trial simulations to accelerate research and strengthen study design.

Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery and preclinical research to clinical trials, regulatory submissions, and market entry, the company's core mission is to accelerate the delivery of new medicines to patients by transforming these processes with its innovative biosimulation software and expertise. Its extensive portfolio of technology-enabled services includes mechanistic and empirical biosimulation, strategic guidance for drug development and regulatory affairs, clinical pharmacology, model-based meta-analysis, specialized regulatory writing and medical communications, regulatory operations support, and market access consultation. Furthermore, Certara offers a robust suite of software platforms covering mechanistic and empirical PK/PD biosimulation, data standardization and compliance, scientific informatics, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions, and market access communication. The company's clientele primarily comprises biopharmaceutical firms, academic institutions, and governmental organizations. Established in 2008 and headquartered in Princeton, New Jersey, Certara maintains a significant global presence, with operations spanning numerous countries including the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China.